chloroquine has been researched along with Recrudescence in 207 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old." | 9.51 | Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. ( Breton, JJ; Chau, NH; Duparc, S; Ernest, TB; Goyal, N; Green, JA; Hien, TT; Hoa, NT; Jones, SW; Martin, A; Mohamed, K; Rolfe, K; Rousell, VM; Sharma, H; Tan, LK; Taylor, M; Vélez, ID, 2022) |
| "Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 9.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 9.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| "Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia." | 9.15 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. ( Bacha, K; Getahun, K; Ketema, T, 2011) |
| "Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria." | 9.15 | Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. ( Ashley, EA; Lindegardh, N; Lwin, KM; Nosten, F; Phyo, AP; Price, RN; Russell, B; Singhasivanon, P; Sriprawat, K; White, NJ, 2011) |
| "In November-December 2002, 98 patients presented at the Elhara Eloula health centre, in the New Halfa area of eastern Sudan, with Plasmodium falciparum malaria that had failed to respond to chloroquine treatment." | 9.11 | Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Aelbasit, IA; Elbashir, MI; Ibrahim, MH; Kheir, MM; Naser, A, 2004) |
| "At a public hospital in Georgetown, Guyana, 44 patients seeking treatment for symptomatic, slide-confirmed malaria were given standard chloroquine (CQ) therapy and followed for 28 days." | 9.10 | Chloroquine for the treatment of uncomplicated malaria in Guyana. ( Baird, JK; Bravet, PP; Carucci, D; Ferrel, M; Hoffman, SL; Martin, GJ; Prout, TM; Rawlins, S; Tamminga, CL; Tiwari, T; Tjaden, J, 2002) |
| "To assess the local efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria, children and adults from Sekong province (an area of Laos with a low intensity of transmission) were tested in a 28-day, in-vivo study." | 9.10 | The efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria in Laos. ( Brockman, A; Garcia, M; Gastellu, M; Guthmann, JP; Kasparian, S; Legros, D; Nathan, N; Phetsouvanh, R; Phompida, S, 2002) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 9.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 9.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| "to assess the efficacy, tolerance and determinants for relapse in patients with porphyria cutanea tarda treated with low-dose oral chloroquine." | 9.07 | Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. ( Ena, J; Enríquez-De-Salamanca, R; Valls, V, 1994) |
| "25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 9.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
| "Longer remissions after the phlebotomy therapy than after the low-dose chloroquine treatment were ascertained by means of the long-term follow-up of a large group of porphyria cutanea tarda patients." | 9.05 | A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. ( Chlumský, J; Malina, L, 1981) |
| "Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')." | 8.98 | Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018) |
| " This study aimed to determine therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone, southern central Ethiopia." | 7.91 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia. ( Bekele, F; Jemal, A; Shumbej, T; Weldesenbet, H; Worku, A, 2019) |
| "We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 7.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
| " We describe a patient with recurrent malaria, prophylactically treated with low-dose chloroquine, who developed heart failure due to biventricular cardiac dysfunction." | 7.75 | Cardiotoxicity after low-dose chloroquine antimalarial therapy. ( Baratto, F; Doglioni, C; Fragasso, G; Margonato, A; Martinenghi, S; Sanvito, F, 2009) |
| "Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine." | 7.74 | Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. ( Edstein, MD; Kitchener, S; Nasveld, P, 2007) |
| "High-dose chloroquine therapy for porphyria cutanea tarda is rarely used now because of its hepatic side-effects." | 7.74 | Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. ( Olsson, R; Rossmann-Ringdahl, I, 2007) |
| "Reports from several sites in South America suggest the presence of isolated cases of chloroquine-resistant Plasmodium vivax malaria." | 7.72 | Chloroquine-resistant Plasmodium vivax malaria in Peru. ( Andersen, EM; Arévalo, E; Cairo, J; Garcia, C; Green, M; Huilca, M; Kain, KC; Marquiño, W; Pillai, DR; Ruebush, TK; Solary, L; Zegarra, J, 2003) |
| "A severe flare-up of chronic hepatitis B infection with liver cell insufficiency has been observed in two patients after discontinuation of chloroquine administered either as malaria prophylaxis or as treatment of presumed rheumatoid arthritis." | 7.69 | [Reactivation of hepatitis B following withdrawal of chloroquine]. ( Helbling, B; Reichen, J, 1994) |
| "Seven patients with porphyria cutanea tarda received a total of ten courses of low-dose oral chloroquine therapy (125 mg chloroquine phosphate twice weekly)." | 7.67 | Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. ( Ashton, RE; Hawk, JL; Magnus, IA, 1984) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 6.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "falciparum for at least 14 days." | 6.68 | Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. ( Alin, MH; Ashton, M; Bjorkman, A; Bwijo, BA; Kihamia, CM; Mtey, GJ; Premji, Z, 1995) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 6.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| "Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old." | 5.51 | Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. ( Breton, JJ; Chau, NH; Duparc, S; Ernest, TB; Goyal, N; Green, JA; Hien, TT; Hoa, NT; Jones, SW; Martin, A; Mohamed, K; Rolfe, K; Rousell, VM; Sharma, H; Tan, LK; Taylor, M; Vélez, ID, 2022) |
| "In addition, on the day of recurrence of parasitaemia the levels of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration (>or=100 etag/ml) in all the three cases, showing that treatment failure could not be attributed to low level of drug in the patients blood." | 5.35 | Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. ( Bacha, K; Birhanu, T; Ketema, T; Petros, B, 2009) |
| "Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 5.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
| " To reduce the side effects, another test was carried out in 3 monkeys and the dosage regimen was modified to pyronaridine 6 mg/kg-artemether 10 mg/kg-chloroquine 20 mg/kg (PAC-2) once daily for 3 days." | 5.29 | [Studies on the establishment of malarial animal model of short-term relapse. III. Combined therapy with pyronaridine-artemether-chloroquine for parasitemia clearance]. ( Fang, Y; Lin, BY; Pan, YR; Zhang, JX; Zheng, H, 1993) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 5.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| "The treatment of chloroquine resistant malaria in West Malaysia is a subject of another paper but suffice it to say that increased doses of chloroquine have still been found to be effective in treating many cases of falciparum malaria from areas of chloroquine resistance." | 5.25 | Chloroquine resistant malaria in West Malaysia. ( Ali, AR; Fredericks, HJ; Ismail, O; Othman, AM; Ponnampalam, JT; Sandosham, AA; Seow, CL, 1975) |
| "Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia." | 5.15 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. ( Bacha, K; Getahun, K; Ketema, T, 2011) |
| "Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria." | 5.15 | Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. ( Ashley, EA; Lindegardh, N; Lwin, KM; Nosten, F; Phyo, AP; Price, RN; Russell, B; Singhasivanon, P; Sriprawat, K; White, NJ, 2011) |
| " We recommend the use of artemisinin-based combination therapy as first-line treatment for uncomplicated Plasmodium falciparum malaria in Koumantou." | 5.12 | Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali. ( de Radiguès, X; Diallo, KI; Diallo, M; Djimdé, A; Doumbo, O; Guthmann, JP; Maiga, H; Ngwakum, PA; Sacko, M, 2006) |
| "In November-December 2002, 98 patients presented at the Elhara Eloula health centre, in the New Halfa area of eastern Sudan, with Plasmodium falciparum malaria that had failed to respond to chloroquine treatment." | 5.11 | Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Aelbasit, IA; Elbashir, MI; Ibrahim, MH; Kheir, MM; Naser, A, 2004) |
| "At a public hospital in Georgetown, Guyana, 44 patients seeking treatment for symptomatic, slide-confirmed malaria were given standard chloroquine (CQ) therapy and followed for 28 days." | 5.10 | Chloroquine for the treatment of uncomplicated malaria in Guyana. ( Baird, JK; Bravet, PP; Carucci, D; Ferrel, M; Hoffman, SL; Martin, GJ; Prout, TM; Rawlins, S; Tamminga, CL; Tiwari, T; Tjaden, J, 2002) |
| "To assess the local efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria, children and adults from Sekong province (an area of Laos with a low intensity of transmission) were tested in a 28-day, in-vivo study." | 5.10 | The efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria in Laos. ( Brockman, A; Garcia, M; Gastellu, M; Guthmann, JP; Kasparian, S; Legros, D; Nathan, N; Phetsouvanh, R; Phompida, S, 2002) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 5.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 5.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| "Chloroquine has been the standard treatment for Plasmodium vivax malaria for more than 40 years in most regions of the world." | 5.09 | Chloroquine sensitivity of Plasmodium vivax in Thailand. ( Bussaratid, V; Chalermrut, K; Chokjindachai, W; Krudsood, S; Looareesuwan, S; Singhasivanon, P; Treeprasertsuk, S; Viriyavejakul, P; Walsh D, S; White, J; Wilairatana, P, 1999) |
| "The present in vivo study evaluates the potential use of ketotifen, a tricyclic antihistaminic drug, in treatment of Sudanese patients with uncomplicated Plasmodium falciparum malaria (19-38 years)." | 5.09 | Ketotifen in treatment of uncomplicated falciparum malaria. ( Elhag, ER; Ibrahim, AM; Mustafa, SE, 2000) |
| "to assess the efficacy, tolerance and determinants for relapse in patients with porphyria cutanea tarda treated with low-dose oral chloroquine." | 5.07 | Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. ( Ena, J; Enríquez-De-Salamanca, R; Valls, V, 1994) |
| "25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 5.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
| "Longer remissions after the phlebotomy therapy than after the low-dose chloroquine treatment were ascertained by means of the long-term follow-up of a large group of porphyria cutanea tarda patients." | 5.05 | A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. ( Chlumský, J; Malina, L, 1981) |
| "Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')." | 4.98 | Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018) |
| "Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure." | 4.98 | The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Erhart, A; Gomes, MSM; Gonzalez-Ceron, L; Grigg, MJ; Guerin, PJ; Heidari, A; Humphreys, GS; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Sutanto, I; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Tran, HT; Valecha, N; Vieira, JLF; Wangchuk, S; White, NJ; William, T; Woodrow, CJ; Zuluaga-Idarraga, L, 2018) |
| "Chloroquine is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but resistance is increasing." | 4.90 | Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. ( Baird, JK; Nosten, F; Price, RN; Valecha, N; von Seidlein, L; White, NJ, 2014) |
| " This study aimed to determine therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone, southern central Ethiopia." | 3.91 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia. ( Bekele, F; Jemal, A; Shumbej, T; Weldesenbet, H; Worku, A, 2019) |
| "We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 3.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
| "Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure." | 3.80 | Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014) |
| "Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections." | 3.79 | Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. ( Alenazi, T; Bright, AT; Houston, S; Paganotti, GM; Shokoples, S; Tarning, J; White, NJ; Winzeler, EA; Yanow, SK, 2013) |
| " We describe a patient with recurrent malaria, prophylactically treated with low-dose chloroquine, who developed heart failure due to biventricular cardiac dysfunction." | 3.75 | Cardiotoxicity after low-dose chloroquine antimalarial therapy. ( Baratto, F; Doglioni, C; Fragasso, G; Margonato, A; Martinenghi, S; Sanvito, F, 2009) |
| "Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine." | 3.74 | Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. ( Edstein, MD; Kitchener, S; Nasveld, P, 2007) |
| "High-dose chloroquine therapy for porphyria cutanea tarda is rarely used now because of its hepatic side-effects." | 3.74 | Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. ( Olsson, R; Rossmann-Ringdahl, I, 2007) |
| "To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar." | 3.74 | Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. ( Annerberg, A; de Radiguès, X; Guthmann, JP; Imwong, M; Lesage, A; Lindegardh, N; Min Lwin, M; Nosten, F; Pittet, A; Zaw, T, 2008) |
| " All recurrent parasitemias occurred with whole blood levels of chloroquine plus desethylchloroquine exceeding 100 ng/ml." | 3.72 | Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. ( Baird, JK; Fryauff, DJ; Leksana, B; Subianto, B; Sumawinata, IW; Sutamihardja, A, 2003) |
| "Reports from several sites in South America suggest the presence of isolated cases of chloroquine-resistant Plasmodium vivax malaria." | 3.72 | Chloroquine-resistant Plasmodium vivax malaria in Peru. ( Andersen, EM; Arévalo, E; Cairo, J; Garcia, C; Green, M; Huilca, M; Kain, KC; Marquiño, W; Pillai, DR; Ruebush, TK; Solary, L; Zegarra, J, 2003) |
| " Whole blood concentrations of chloroquine, sulfadoxine, and quinine were determined at different intervals and at the time of parasites recrudescence after completion of treatment with the respective drugs to confirm the status of drug sensitivity." | 3.72 | Multi-drug resistant Plasmodium falciparum malaria in Assam, India: timing of recurrence and anti-malarial drug concentrations in whole blood. ( Dev, V; Dua, VK; Gupta, NC; Phookan, S; Sharma, VP; Subbarao, SK, 2003) |
| "A severe flare-up of chronic hepatitis B infection with liver cell insufficiency has been observed in two patients after discontinuation of chloroquine administered either as malaria prophylaxis or as treatment of presumed rheumatoid arthritis." | 3.69 | [Reactivation of hepatitis B following withdrawal of chloroquine]. ( Helbling, B; Reichen, J, 1994) |
| "The efficacity of oral chloroquine was assessed in 360 out-clinic patients with symptomatic Plasmodium falciparum malaria who were enrolled at five sites, in four administrative regions of Senegal, between 1991 and 1995." | 3.69 | [In vivo chemosensitivity tests of Plasmodium falciparum to chloroquine in Senegal: the development of resistance and the assessment of therapeutic efficacy]. ( Molez, JF; Ndiaye, P; Sane, B; Sokhna, CS; Trape, JF, 1997) |
| "A 56-year-old patient suffering from porphyria cutanea tarda (PCT) was sufficiently treated with chloroquine and occasional bleeding." | 3.68 | [Artefacts in porphyria cutanea tarda]. ( Egger, B; Goerz, G, 1990) |
| "Seven patients with porphyria cutanea tarda received a total of ten courses of low-dose oral chloroquine therapy (125 mg chloroquine phosphate twice weekly)." | 3.67 | Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. ( Ashton, RE; Hawk, JL; Magnus, IA, 1984) |
| "9 per cent relapse rate after administration of radical treatment of primaquine / 15 mg daily for 5 days as followed under the National Malaria Eradication Programme." | 3.67 | Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.). ( Dua, VK; Sharma, VP; Sinha, S, 1989) |
| "215 patients of vivax malaria were treated with chloroquine phosphate alone at the dose of 1." | 3.67 | [Field observation on the relapse pattern in patients naturally infected with vivax malaria from spring to autumn seasons in Cili County, Hunan Province]. ( Li, QJ; Liu, WJ; Yang, BL; Yuan, HA; Zhu, FH, 1989) |
| "Within two months of treatment for falciparum malaria, Plasmodium vivax infections developed in 58 (33%) of 174 patients who had received a quinine or quinidine regimen and in 46 (32%) of 145 patients who had received mefloquine with inpatient follow-up of more than six weeks." | 3.67 | High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. ( Bunnag, D; Chittamas, S; Harinasuta, T; Looareesuwan, S; White, NJ, 1987) |
| "Some parasite recurrences were detected by PCR and/or serological testing." | 2.80 | Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. ( Betanzos, AF; Galindo-Virgen, S; Gonzalez-Ceron, L; Palomeque, OL; Rodriguez, MH; Rosales, AF; Sandoval, MA; Santillan, F, 2015) |
| "This suggested that 32 of the 47 recurrences were probable relapses of which 22 (69%) were genetically homologous." | 2.77 | Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. ( Addy, M; Day, NP; Dondorp, AM; Imwong, M; Kim, JR; Maji, AK; Nandy, A; Pukrittayakamee, S; White, NJ, 2012) |
| "Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in Indonesia before the initial launch of artemisinin combination therapy in 2004." | 2.75 | Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. ( Baird, JK; Endawati, D; Laihad, F; Ling, LH; Setiabudy, R; Sutanto, I, 2010) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 2.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia." | 2.70 | Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. ( Ayomi, E; Baird, JK; Basri, H; Fryauff, DJ; Hoffman, SL; Sutanihardja, A; Wiady, I, 2002) |
| "falciparum for at least 14 days." | 2.68 | Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. ( Alin, MH; Ashton, M; Bjorkman, A; Bwijo, BA; Kihamia, CM; Mtey, GJ; Premji, Z, 1995) |
| "The efficacy and toxicity of oral quinine combined with oral chloroquine were studied in 50 Thai men with uncomplicated falciparum malaria." | 2.68 | Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria. ( Chantra, A; Chindanond, D; Clemens, R; Phophak, N; Pukrittayakamee, S; Vanijanonta, S, 1996) |
| "Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0." | 2.68 | Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997) |
| "falciparum." | 2.68 | In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. ( Baird, JK; Fryauff, DJ; Leksana, B; Subianto, B; Sutanihardja, MA; Wiady, I; Widjaya, H, 1997) |
| "Chloroquine treatment cured 15 patients (36%)." | 2.67 | Curing of chloroquine-resistant malaria with clindamycin. ( Bienzle, U; Brandts, C; Graninger, W; Kremsner, PG; Winkler, S, 1993) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 2.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| " For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents." | 2.41 | [Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000) |
| "If the recurrence appears before day 16, it is almost certainly a recrudescence and between days 17 and 28 it may be either a recrudescence or a relapse by chloroquine-resistant parasites." | 2.40 | Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. ( Baird, JK; Fryauff, DJ; Hoffman, SL; Leksana, B; Masbar, S; Sutanihardja, MA; Wignall, FS, 1997) |
| "Relapses in vivax malaria have posed great challenges for malaria control, and they also account for a great proportion of reported cases." | 1.62 | Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. ( Brito-Sousa, JD; Dinelly, KMO; Lacerda, MVG; Melo, GC; Monteiro, WM; Omena, AG; Peterka, C; Rodovalho, S; Sampaio, VS; Silva, MGO; Siqueira, AM; Vitor-Silva, S, 2021) |
| "We compare recurrence rates observed after primary P." | 1.56 | Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020) |
| "There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1." | 1.51 | Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019) |
| "vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0." | 1.51 | Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. ( Adhikari, B; Banjara, MR; Chotivanich, K; Das Thakur, G; Day, NPJ; Ghimire, P; Hanboonkunupakarn, B; Imwong, M; Pukrittayakamee, S; Rijal, KR; White, NJ, 2019) |
| "Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models." | 1.51 | Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. ( A Cleves, M; Aguirre, AR; D'Alessandro, U; Erhart, A; Hens, N; Le, HX; Nguyen, HV; Nguyen, TT; Nguyen, VV; Nguyen, XX; Pham, TV; Rosanas-Urgell, A; Speybroeck, N; Tran, DT, 2019) |
| "vivax malaria episode until the recurrence did not differ between patients with AS of ≤ 1 versus ≥ 1." | 1.48 | CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( Almeida, ACG; Brasil, LW; Kühn, A; Lacerda, MVG; Monteiro, WM; Ramasawmy, R; Rodrigues-Soares, F; Santoro, AB; Suarez-Kurtz, G, 2018) |
| "vivax malaria is a substantial risk." | 1.40 | Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014) |
| "falciparum malaria was evaluated in the Anand district of Gujarat state, in western India." | 1.35 | Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates. ( Dash, AP; Joshi, H; Mallick, PK; Prajapati, SK; Srivastava, HC; Valecha, N; Yadav, RS, 2008) |
| "Parasite recrudescences in 33 consecutive paired episodes during the same pregnancy were identified by msp1 and msp2 genotyping." | 1.35 | Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| "In addition, on the day of recurrence of parasitaemia the levels of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration (>or=100 etag/ml) in all the three cases, showing that treatment failure could not be attributed to low level of drug in the patients blood." | 1.35 | Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. ( Bacha, K; Birhanu, T; Ketema, T; Petros, B, 2009) |
| "Here we describe high rates of P." | 1.35 | Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009) |
| "Treatment with chloroquine was initiated, with almost complete recovery by 5 months." | 1.31 | Kikuchi-Fujimoto necrotizing lymphadenitis associated with cutaneous lupus erythematosus: a case report. ( Chopite, M; Lopez, C; Olavarria, R; Oliver, M; Sarabia, MA, 2000) |
| "vivax parasitemias were sensitive to chloroquine and the blood remained clear, with the exception of one case in which an asymptomatic parasitemia appeared on day 28." | 1.30 | Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. ( Baird, JK; Candradikusuma, D; Fryauff, DJ; Leksana, B; Marwoto, H; Masbar, S; Richie, T; Romzan, A; Sutamihardja, MA; Tuti, S, 1997) |
| "Chronic ulcerative stomatitis (CUS), a rare disease of oral mucosa found to be associated with unusual antinuclear antibodies reactive exclusively with squamous epithelia (squamous epithelium-specific antinuclear antibodies - SES-ANA), has been reported to occur almost exclusively in older females and to respond dramatically to antimalarials." | 1.30 | Is chronic ulcerative stomatitis an entity? Clinical and immunological findings in 18 cases. ( Chorzelski, TP; Jablonska, S; Jarzabek-Chorzelska, M; Olszewska, M, 1998) |
| "Chloroquine was prescribed at 25 mg/kg for 3 days in febrile patients with uncomplicated P." | 1.30 | [Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. ( Ali, I; Bendavid, C; Condomines, P; Crassard, N; Djermakoye, F; Faugère, B; Parola, P, 1999) |
| " To reduce the side effects, another test was carried out in 3 monkeys and the dosage regimen was modified to pyronaridine 6 mg/kg-artemether 10 mg/kg-chloroquine 20 mg/kg (PAC-2) once daily for 3 days." | 1.29 | [Studies on the establishment of malarial animal model of short-term relapse. III. Combined therapy with pyronaridine-artemether-chloroquine for parasitemia clearance]. ( Fang, Y; Lin, BY; Pan, YR; Zhang, JX; Zheng, H, 1993) |
| "Primaquine has been found adequate to prevent relapse in more than 90% vivax cases, while efficacy of chloroquine-pyrimethamine and chloroquine alone was almost comparable." | 1.29 | Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. ( Bhatt, RM; Sharma, SK; Sharma, VP; Srivastava, HC, 1996) |
| " In nine of 13 patients who received prophylaxis, there was inadequate dosing or poor compliance." | 1.28 | Imported malaria in the Bronx: review of 51 cases recorded from 1986 to 1991. ( Froude, JR; Tanowitz, HB; Weiss, LM; Wittner, M, 1992) |
| "Recrudescence was confirmed by microscopic examination, indicating a type RI resistance to halofantrine." | 1.28 | Type RI resistance to halofantrine in West Africa. ( Basco, LK; Bouchaud, O; Coulaud, JP; Farinotti, R; Gillotin, C; Gimenez, F; Le Bras, J; Rabenjarson, E; Ringwald, P, 1991) |
| "Chloroquine was most frequently used among antimalarial agents (in 123 cases, 65% of the total) for suppressing acute attacks." | 1.28 | [Clinical evaluation of antimalarial drugs]. ( Shimada, K; Tanabe, K, 1990) |
| "Treatment with chloroquine 1." | 1.28 | [Experimental studies on the incubation period and relapse patterns in vivax malaria in west Hunan]. ( He, YZ; Huang, Z; Li, QJ; Pang, LL; Tang, LY; Wang, WJ; Wang, ZM; Yang, BL; Zhang, XJ, 1989) |
| " Nineteen patients had ocular manifestations of giant cell arteritis always from the onset, except for a fall in visual acuity; 26 relapses were observed in 18 patients, either during reduction of steroid dosage (21 cases) or after withdrawal (5 cases)." | 1.27 | [Prognosis of treated temporal arteritis. Retrospective study of 87 cases]. ( Alcalay, M; Becq-Giraudon, B; Boissonnot, L; Bontoux, D; Gil, R; Gouet, D; Le Berre, D; Lefevre, JP; Maréchaud, R; Risse, JF, 1986) |
| "The actual situation of the treatment of malaria for the past 10 years in Japan was investigated and analyzed." | 1.27 | Clinical evaluation of antimalarial regimens in Japan. ( Hioki, A; Ishizaki, T; Nakabayashi, T; Ohtomo, H; Tanabe, K, 1987) |
| "Pulmonary disease was the major manifestation in 70% and was present in 88%." | 1.27 | Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. ( Johns, CJ; MacGregor, MI; Schonfeld, SA; Scott, PP; Zachary, JB, 1986) |
| "Chloroquine pressure was applied over a 22 month period on a somewhat isolated, malarious rubber estate by examination of residents at 4-week intervals and treatment of parasitaemias with chloroquine." | 1.25 | Increased frequency of chloroquine resistant P. falciparum on a rubber estate in Peninsular Malaysia during two years of systematic chloroquine treatment. ( Dondero, TJ; O'Holohan, DR; Parsons, RE, 1975) |
| "The treatment of chloroquine resistant malaria in West Malaysia is a subject of another paper but suffice it to say that increased doses of chloroquine have still been found to be effective in treating many cases of falciparum malaria from areas of chloroquine resistance." | 1.25 | Chloroquine resistant malaria in West Malaysia. ( Ali, AR; Fredericks, HJ; Ismail, O; Othman, AM; Ponnampalam, JT; Sandosham, AA; Seow, CL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 69 (33.33) | 18.7374 |
| 1990's | 47 (22.71) | 18.2507 |
| 2000's | 46 (22.22) | 29.6817 |
| 2010's | 37 (17.87) | 24.3611 |
| 2020's | 8 (3.86) | 2.80 |
| Authors | Studies |
|---|---|
| Hasugian, AR | 1 |
| Tjitra, E | 3 |
| Ratcliff, A | 2 |
| Siswantoro, H | 2 |
| Kenangalem, E | 2 |
| Wuwung, RM | 1 |
| Purba, HL | 1 |
| Piera, KA | 1 |
| Chalfien, F | 1 |
| Marfurt, J | 1 |
| Penttinen, PM | 1 |
| Russell, B | 2 |
| Anstey, NM | 3 |
| Price, RN | 6 |
| Vélez, ID | 1 |
| Hien, TT | 1 |
| Green, JA | 1 |
| Martin, A | 1 |
| Sharma, H | 1 |
| Rousell, VM | 1 |
| Breton, JJ | 1 |
| Ernest, TB | 1 |
| Rolfe, K | 1 |
| Taylor, M | 1 |
| Mohamed, K | 1 |
| Jones, SW | 1 |
| Chau, NH | 1 |
| Hoa, NT | 1 |
| Duparc, S | 1 |
| Tan, LK | 1 |
| Goyal, N | 1 |
| Chamma-Siqueira, NN | 1 |
| Negreiros, SC | 1 |
| Ballard, SB | 1 |
| Farias, S | 2 |
| Silva, SP | 1 |
| Chenet, SM | 2 |
| Santos, EJM | 1 |
| Pereira de Sena, LW | 1 |
| Póvoa da Costa, F | 1 |
| Cardoso-Mello, AGN | 1 |
| Marchesini, PB | 1 |
| Peterka, CRL | 1 |
| Viana, GMR | 1 |
| Macedo de Oliveira, A | 1 |
| He, X | 1 |
| Pan, M | 1 |
| Zeng, W | 1 |
| Zou, C | 1 |
| Pi, L | 1 |
| Qin, Y | 1 |
| Zhao, L | 1 |
| Qin, P | 1 |
| Lu, Y | 1 |
| Baird, JK | 12 |
| Huang, Y | 1 |
| Cui, L | 1 |
| Yang, Z | 1 |
| Camarlinghi, G | 1 |
| Parisio, EM | 1 |
| Nardone, M | 1 |
| Mancini, F | 1 |
| Ciervo, A | 1 |
| Boccolini, D | 1 |
| Mattei, R | 1 |
| Mishra, R | 1 |
| Kohli, S | 1 |
| Malhotra, N | 1 |
| Bandyopadhyay, P | 1 |
| Mehta, M | 1 |
| Munshi, M | 1 |
| Adiga, V | 1 |
| Ahuja, VK | 1 |
| Shandil, RK | 1 |
| Rajmani, RS | 1 |
| Seshasayee, ASN | 1 |
| Singh, A | 1 |
| Devine, A | 1 |
| Howes, RE | 1 |
| Price, DJ | 1 |
| Moore, KA | 2 |
| Ley, B | 2 |
| Simpson, JA | 2 |
| Dittrich, S | 1 |
| Castro-Cavadía, CJ | 1 |
| Carmona-Fonseca, J | 1 |
| Corder, RM | 1 |
| de Lima, ACP | 1 |
| Khoury, DS | 1 |
| Docken, SS | 1 |
| Davenport, MP | 1 |
| Ferreira, MU | 2 |
| Rodrigo, C | 1 |
| Rajapakse, S | 1 |
| Fernando, D | 1 |
| Balieiro, AAS | 1 |
| Siqueira, AM | 4 |
| Melo, GC | 3 |
| Monteiro, WM | 4 |
| Sampaio, VS | 2 |
| Mueller, I | 3 |
| Lacerda, MVG | 4 |
| Villela, DAM | 1 |
| Dinelly, KMO | 1 |
| Vitor-Silva, S | 1 |
| Brito-Sousa, JD | 1 |
| Silva, MGO | 1 |
| Peterka, C | 1 |
| Rodovalho, S | 1 |
| Omena, AG | 1 |
| Wampfler, R | 1 |
| Hofmann, NE | 1 |
| Karl, S | 1 |
| Betuela, I | 1 |
| Kinboro, B | 1 |
| Lorry, L | 1 |
| Silkey, M | 1 |
| Robinson, LJ | 1 |
| Felger, I | 3 |
| Islam, S | 1 |
| Hai, F | 1 |
| Brasil, LW | 1 |
| Rodrigues-Soares, F | 1 |
| Santoro, AB | 1 |
| Almeida, ACG | 1 |
| Kühn, A | 1 |
| Ramasawmy, R | 1 |
| Suarez-Kurtz, G | 1 |
| Recht, J | 1 |
| Ashley, EA | 2 |
| White, NJ | 15 |
| Chu, CS | 3 |
| Phyo, AP | 4 |
| Lwin, KM | 2 |
| Win, HH | 2 |
| San, T | 1 |
| Aung, AA | 1 |
| Raksapraidee, R | 2 |
| Carrara, VI | 2 |
| Bancone, G | 2 |
| Watson, J | 2 |
| Wiladphaingern, J | 2 |
| Proux, S | 2 |
| Sriprawat, K | 3 |
| Winterberg, M | 1 |
| Cheah, PY | 1 |
| Chue, AL | 1 |
| Tarning, J | 3 |
| Imwong, M | 7 |
| Nosten, F | 7 |
| Commons, RJ | 1 |
| Thriemer, K | 1 |
| Humphreys, GS | 1 |
| Abreha, T | 1 |
| Alemu, SG | 1 |
| Añez, A | 1 |
| Awab, GR | 2 |
| Barber, BE | 1 |
| Borghini-Fuhrer, I | 1 |
| D'Alessandro, U | 2 |
| Dahal, P | 1 |
| Daher, A | 2 |
| de Vries, PJ | 1 |
| Erhart, A | 2 |
| Gomes, MSM | 1 |
| Gonzalez-Ceron, L | 3 |
| Grigg, MJ | 1 |
| Heidari, A | 1 |
| Hwang, J | 1 |
| Kager, PA | 1 |
| Ketema, T | 3 |
| Khan, WA | 1 |
| Leslie, T | 1 |
| Lidia, K | 1 |
| Pereira, DB | 1 |
| Phan, GT | 1 |
| Rowland, M | 2 |
| Saravu, K | 1 |
| Sibley, CH | 1 |
| Stepniewska, K | 1 |
| Sutanto, I | 2 |
| Taylor, WRJ | 1 |
| Thwaites, G | 1 |
| Tran, BQ | 1 |
| Tran, HT | 1 |
| Valecha, N | 4 |
| Vieira, JLF | 1 |
| Wangchuk, S | 1 |
| William, T | 1 |
| Woodrow, CJ | 2 |
| Zuluaga-Idarraga, L | 1 |
| Guerin, PJ | 1 |
| Popovici, J | 1 |
| Pierce-Friedrich, L | 1 |
| Kim, S | 1 |
| Bin, S | 1 |
| Run, V | 1 |
| Lek, D | 1 |
| Hee, KHD | 1 |
| Lee Soon-U, L | 1 |
| Cannon, MV | 1 |
| Serre, D | 1 |
| Menard, D | 1 |
| Redditt, V | 1 |
| Bogoch, I | 1 |
| Rashid, M | 1 |
| Silva, JCAL | 1 |
| Stevens, A | 1 |
| Marchesini, P | 2 |
| Fontes, CJ | 2 |
| Ter Kuile, FO | 1 |
| Lalloo, DG | 1 |
| Rijal, KR | 1 |
| Adhikari, B | 1 |
| Ghimire, P | 1 |
| Banjara, MR | 1 |
| Das Thakur, G | 1 |
| Hanboonkunupakarn, B | 1 |
| Chotivanich, K | 1 |
| Day, NPJ | 1 |
| Pukrittayakamee, S | 6 |
| Turner, C | 1 |
| Poe, NP | 1 |
| Yotyingaphiram, W | 1 |
| Thinraow, S | 1 |
| Wilairisak, P | 1 |
| Paw, MK | 1 |
| Lee, SJ | 2 |
| Jeeyapant, A | 1 |
| Shumbej, T | 1 |
| Jemal, A | 1 |
| Worku, A | 1 |
| Bekele, F | 1 |
| Weldesenbet, H | 1 |
| Pham, TV | 1 |
| Nguyen, HV | 1 |
| Aguirre, AR | 1 |
| Nguyen, VV | 1 |
| A Cleves, M | 1 |
| Nguyen, XX | 1 |
| Nguyen, TT | 1 |
| Tran, DT | 1 |
| Le, HX | 1 |
| Hens, N | 1 |
| Rosanas-Urgell, A | 1 |
| Speybroeck, N | 1 |
| Ye, Z | 1 |
| Van Dyke, K | 1 |
| Rossan, RN | 2 |
| Bright, AT | 1 |
| Alenazi, T | 1 |
| Shokoples, S | 1 |
| Paganotti, GM | 1 |
| Houston, S | 1 |
| Winzeler, EA | 1 |
| Yanow, SK | 1 |
| Durand, S | 1 |
| Cabezas, C | 1 |
| Lescano, AG | 1 |
| Galvez, M | 1 |
| Gutierrez, S | 1 |
| Arrospide, N | 1 |
| Alvarez, C | 1 |
| Santolalla, ML | 1 |
| Bacon, DJ | 1 |
| Graf, PC | 1 |
| Møller, CH | 1 |
| David, K | 1 |
| Dos-Santos, JC | 1 |
| Angerami, RN | 1 |
| Castiñeiras, CM | 1 |
| Lopes, SC | 1 |
| Albrecht, L | 1 |
| Garcia, MT | 1 |
| Levy, CE | 1 |
| Moretti, ML | 1 |
| Lacerda, MV | 2 |
| Costa, FT | 1 |
| von Seidlein, L | 1 |
| Saunders, D | 1 |
| Vanachayangkul, P | 1 |
| Imerbsin, R | 1 |
| Khemawoot, P | 1 |
| Siripokasupkul, R | 1 |
| Tekwani, BL | 1 |
| Sampath, A | 1 |
| Nanayakkara, NP | 1 |
| Ohrt, C | 1 |
| Lanteri, C | 1 |
| Gettyacamin, M | 1 |
| Teja-Isavadharm, P | 1 |
| Walker, L | 1 |
| Redig, AJ | 1 |
| Vaidya, A | 1 |
| Price, C | 1 |
| Katz, JT | 1 |
| Maguire, JH | 1 |
| Cheoymang, A | 1 |
| Ruenweerayut, R | 1 |
| Muhamad, P | 1 |
| Rungsihirunrat, K | 1 |
| Na-Bangchang, K | 1 |
| Erhardt, J | 1 |
| Frank, M | 1 |
| Rodriguez, MH | 2 |
| Sandoval, MA | 1 |
| Santillan, F | 1 |
| Galindo-Virgen, S | 1 |
| Betanzos, AF | 1 |
| Rosales, AF | 1 |
| Palomeque, OL | 1 |
| Zuluaga-Idarraga, LM | 1 |
| Tamayo Perez, ME | 1 |
| Aguirre-Acevedo, DC | 1 |
| Negreiros, S | 1 |
| Viana, GM | 1 |
| Okoth, SA | 1 |
| de Souza, TM | 1 |
| Udhayakumar, V | 1 |
| Povoa, MM | 1 |
| Santelli, AC | 1 |
| de Oliveira, AM | 1 |
| Alencar, AC | 1 |
| Magalhaes, BL | 1 |
| Machado, K | 1 |
| Alencar Filho, AC | 1 |
| Kuehn, A | 1 |
| Marques, MM | 1 |
| Manso, MC | 1 |
| Vieira, JL | 1 |
| Lameyre, V | 1 |
| Daniel-Ribeiro, CT | 1 |
| Al Hammadi, A | 1 |
| Mitchell, M | 1 |
| Abraham, GM | 1 |
| Wang, JP | 1 |
| Seifu, S | 1 |
| Zeynudin, A | 1 |
| Zemene, E | 1 |
| Suleman, S | 1 |
| Biruksew, A | 1 |
| Srivastava, HC | 2 |
| Yadav, RS | 1 |
| Joshi, H | 1 |
| Mallick, PK | 1 |
| Prajapati, SK | 1 |
| Dash, AP | 1 |
| Collins, WE | 7 |
| Sullivan, JS | 3 |
| Nace, D | 1 |
| Williams, T | 1 |
| Williams, A | 1 |
| Barnwell, JW | 1 |
| Teka, H | 1 |
| Petros, B | 2 |
| Yamuah, L | 1 |
| Tesfaye, G | 1 |
| Elhassan, I | 1 |
| Muchohi, S | 1 |
| Kokwaro, G | 1 |
| Aseffa, A | 1 |
| Engers, H | 1 |
| Karunajeewa, HA | 1 |
| Senn, M | 1 |
| Lin, E | 1 |
| Law, I | 1 |
| Gomorrai, PS | 1 |
| Oa, O | 1 |
| Griffin, S | 1 |
| Kotab, K | 1 |
| Suano, P | 1 |
| Tarongka, N | 1 |
| Ura, A | 1 |
| Lautu, D | 1 |
| Page-Sharp, M | 1 |
| Wong, R | 1 |
| Salman, S | 1 |
| Siba, P | 1 |
| Ilett, KF | 2 |
| Davis, TM | 2 |
| Mayor, A | 1 |
| Serra-Casas, E | 1 |
| Bardají, A | 1 |
| Sanz, S | 1 |
| Puyol, L | 1 |
| Cisteró, P | 1 |
| Sigauque, B | 1 |
| Mandomando, I | 1 |
| Aponte, JJ | 1 |
| Alonso, PL | 1 |
| Menéndez, C | 1 |
| Bacha, K | 2 |
| Birhanu, T | 1 |
| Fragasso, G | 1 |
| Sanvito, F | 1 |
| Baratto, F | 1 |
| Martinenghi, S | 1 |
| Doglioni, C | 1 |
| Margonato, A | 1 |
| Hanf, M | 1 |
| Stéphani, A | 1 |
| Basurko, C | 1 |
| Nacher, M | 1 |
| Carme, B | 1 |
| Orjuela-Sánchez, P | 1 |
| da Silva, NS | 1 |
| da Silva-Nunes, M | 1 |
| Endawati, D | 1 |
| Ling, LH | 1 |
| Laihad, F | 2 |
| Setiabudy, R | 1 |
| Dondorp, AM | 2 |
| Day, NP | 3 |
| Singhasivanon, P | 3 |
| Kaker, F | 1 |
| Getahun, K | 1 |
| Lindegardh, N | 2 |
| Kim, JR | 2 |
| Nandy, A | 2 |
| Maji, AK | 1 |
| Addy, M | 1 |
| Tiwari, T | 1 |
| Martin, GJ | 1 |
| Tamminga, CL | 1 |
| Prout, TM | 1 |
| Tjaden, J | 1 |
| Bravet, PP | 1 |
| Rawlins, S | 1 |
| Ferrel, M | 1 |
| Carucci, D | 1 |
| Hoffman, SL | 4 |
| Wiady, I | 3 |
| Sutanihardja, A | 1 |
| Basri, H | 2 |
| Ayomi, E | 1 |
| Fryauff, DJ | 6 |
| Guthmann, JP | 4 |
| Kasparian, S | 1 |
| Phetsouvanh, R | 1 |
| Nathan, N | 1 |
| Garcia, M | 1 |
| Phompida, S | 1 |
| Brockman, A | 2 |
| Gastellu, M | 1 |
| Legros, D | 1 |
| Durante Mangoni, E | 1 |
| Severini, C | 1 |
| Menegon, M | 1 |
| Romi, R | 1 |
| Ruggiero, G | 1 |
| Majori, G | 1 |
| Mehrunnisa, A | 1 |
| Saifi, MA | 1 |
| Khan, HM | 1 |
| Sowunmi, A | 4 |
| Sumawinata, IW | 1 |
| Leksana, B | 4 |
| Sutamihardja, A | 1 |
| Subianto, B | 3 |
| Fateye, BA | 1 |
| LAPIERRE, J | 1 |
| JEFFERY, GM | 2 |
| MACAULAY, WL | 1 |
| Ruebush, TK | 2 |
| Zegarra, J | 1 |
| Cairo, J | 1 |
| Andersen, EM | 1 |
| Green, M | 1 |
| Pillai, DR | 1 |
| Marquiño, W | 1 |
| Huilca, M | 1 |
| Arévalo, E | 1 |
| Garcia, C | 1 |
| Solary, L | 1 |
| Kain, KC | 2 |
| Dua, VK | 2 |
| Dev, V | 1 |
| Phookan, S | 1 |
| Gupta, NC | 1 |
| Sharma, VP | 4 |
| Subbarao, SK | 1 |
| Happi, CT | 1 |
| Gbotosho, GO | 1 |
| Falade, CO | 1 |
| Akinboye, DO | 1 |
| Gerena, L | 1 |
| Kyle, DE | 2 |
| Milhous, W | 1 |
| Wirth, DF | 1 |
| Oduola, AM | 1 |
| Ibrahim, MH | 1 |
| Elbashir, MI | 1 |
| Naser, A | 1 |
| Aelbasit, IA | 1 |
| Kheir, MM | 1 |
| Adam, I | 1 |
| Smithuis, F | 1 |
| Shahmanesh, M | 1 |
| Kyaw, MK | 1 |
| Savran, O | 1 |
| Lwin, S | 1 |
| de Radiguès, X | 2 |
| Diallo, KI | 1 |
| Diallo, M | 1 |
| Ngwakum, PA | 1 |
| Maiga, H | 1 |
| Djimdé, A | 1 |
| Sacko, M | 1 |
| Doumbo, O | 1 |
| Wuwung, M | 1 |
| Edstein, MD | 2 |
| Ebsworth, EP | 1 |
| Snounou, G | 1 |
| Tanomsing, N | 1 |
| Carlton, J | 1 |
| Looareesuwan, S | 6 |
| Nair, S | 1 |
| Sudimack, D | 1 |
| Anderson, TJ | 1 |
| Ma, SH | 1 |
| Zheng, L | 1 |
| Liu, YJ | 1 |
| Guo, SY | 1 |
| Feng, H | 1 |
| Chen, G | 1 |
| Li, DM | 1 |
| Wang, JC | 1 |
| Cao, YM | 1 |
| Kitchener, S | 1 |
| Nasveld, P | 1 |
| Silai, R | 1 |
| Moussa, M | 1 |
| Abdalli Mari, M | 1 |
| Astafieva-Djaza, M | 1 |
| Hafidhou, M | 1 |
| Oumadi, A | 1 |
| Randrianarivelojosia, M | 1 |
| Said Ankili, A | 1 |
| Said Ahmed, B | 1 |
| Gayibor, AH | 1 |
| Ariey, F | 1 |
| Ringwald, P | 2 |
| Kulthanan, K | 1 |
| Thumpimukvatana, N | 1 |
| Rossmann-Ringdahl, I | 1 |
| Olsson, R | 1 |
| Coldren, RL | 1 |
| Jongsakul, K | 1 |
| Vayakornvichit, S | 1 |
| Noedl, H | 2 |
| Fukudas, MM | 1 |
| Pittet, A | 1 |
| Lesage, A | 1 |
| Min Lwin, M | 1 |
| Zaw, T | 1 |
| Annerberg, A | 1 |
| Herzog, C | 1 |
| Ellis, CJ | 1 |
| Innes, JA | 1 |
| Fletcher, KA | 1 |
| Watkins, WM | 1 |
| Sixsmith, DG | 1 |
| Spencer, HC | 1 |
| Boriga, DA | 1 |
| Kariuki, DM | 1 |
| Kipingor, T | 1 |
| Koech, DK | 1 |
| Malina, L | 1 |
| Chlumský, J | 1 |
| Wang, K | 1 |
| Liu, YL | 1 |
| Zhang, PN | 1 |
| Liu, JX | 1 |
| Appavoo, NC | 1 |
| Roy, RG | 2 |
| Kapali, V | 1 |
| Ashton, RE | 1 |
| Hawk, JL | 1 |
| Magnus, IA | 1 |
| Dutta, GP | 3 |
| Kamboj, KK | 1 |
| Poltera, AA | 1 |
| Wennersten, G | 1 |
| Ros, AM | 1 |
| Krivosheev, BN | 1 |
| Pazzaglia, G | 1 |
| Woodward, WE | 1 |
| Horstmann, P | 2 |
| Kint, A | 1 |
| de Cuyper, C | 1 |
| Jelinek, T | 1 |
| Nothdurft, HD | 1 |
| Von Sonnenburg, F | 1 |
| Loscher, T | 1 |
| Van den Abbeele, K | 1 |
| Van den Enden, E | 2 |
| Van den Ende, J | 2 |
| Valls, V | 1 |
| Ena, J | 1 |
| Enríquez-De-Salamanca, R | 1 |
| Cranfield, MR | 1 |
| Graczyk, TK | 1 |
| Beall, FB | 1 |
| Ialeggio, DM | 1 |
| Shaw, ML | 1 |
| Skjoldager, ML | 1 |
| Zhang, JX | 3 |
| Lin, BY | 3 |
| Pan, YR | 2 |
| Zheng, H | 2 |
| Tang, WZ | 1 |
| Chen, YD | 1 |
| Xu, B | 1 |
| Gazin, PP | 1 |
| Vanijanonta, S | 2 |
| Chantra, A | 2 |
| Clemens, R | 2 |
| Fang, Y | 1 |
| Helbling, B | 1 |
| Reichen, J | 1 |
| Kremsner, PG | 1 |
| Winkler, S | 1 |
| Brandts, C | 1 |
| Graninger, W | 1 |
| Bienzle, U | 1 |
| Tripathi, KD | 1 |
| Sharma, AK | 1 |
| Kulpati, DD | 1 |
| Alin, MH | 1 |
| Kihamia, CM | 1 |
| Bjorkman, A | 1 |
| Bwijo, BA | 1 |
| Premji, Z | 1 |
| Mtey, GJ | 1 |
| Ashton, M | 1 |
| Phophak, N | 1 |
| Chindanond, D | 1 |
| Sorabjee, JS | 1 |
| Signorini, L | 1 |
| Matteelli, A | 1 |
| Castelnuovo, F | 1 |
| Castelli, F | 1 |
| Oladeji, O | 1 |
| Carosi, G | 1 |
| Candradikusuma, D | 1 |
| Masbar, S | 2 |
| Sutamihardja, MA | 1 |
| Tuti, S | 1 |
| Marwoto, H | 1 |
| Richie, T | 1 |
| Romzan, A | 1 |
| Bangs, MJ | 1 |
| Harjosuwarno, S | 1 |
| Richie, TL | 1 |
| Sharma, SK | 1 |
| Bhatt, RM | 1 |
| Bhatia, MS | 1 |
| Sutanihardja, MA | 2 |
| Wignall, FS | 1 |
| Widjaya, H | 1 |
| Nayar, JK | 1 |
| Baker, RH | 1 |
| Knight, JW | 1 |
| Morris, CL | 3 |
| Richardson, BB | 2 |
| Galland, GG | 2 |
| Sokhna, CS | 1 |
| Molez, JF | 1 |
| Ndiaye, P | 1 |
| Sane, B | 1 |
| Trape, JF | 1 |
| Shah, I | 1 |
| Mehmood, P | 1 |
| Mujahid, C | 1 |
| Razique, F | 1 |
| Hewitt, S | 1 |
| Durrani, N | 1 |
| al-Yaman, F | 1 |
| Genton, B | 1 |
| Mokela, D | 1 |
| Narara, A | 1 |
| Raiko, A | 1 |
| Alpers, MP | 1 |
| Buchachart, K | 1 |
| Wilairatana, P | 4 |
| Chalermrut, K | 2 |
| Rattanapong, Y | 1 |
| Amradee, S | 1 |
| Siripiphat, S | 1 |
| Chullawichit, S | 1 |
| Thimasan, K | 1 |
| Ittiverakul, M | 1 |
| Triampon, A | 1 |
| Walsh, DS | 2 |
| Nguyen-Dinh, P | 1 |
| Nesby, S | 1 |
| Chorzelski, TP | 1 |
| Olszewska, M | 1 |
| Jarzabek-Chorzelska, M | 1 |
| Jablonska, S | 1 |
| Irion, A | 1 |
| Abdulla, S | 1 |
| Smith, T | 1 |
| Mull, R | 1 |
| Tanner, M | 1 |
| Hatz, C | 1 |
| Beck, HP | 1 |
| Na, DJ | 1 |
| Han, JD | 1 |
| Cha, DY | 1 |
| Song, IK | 1 |
| Choi, HW | 1 |
| Chung, EA | 1 |
| Park, CW | 1 |
| Choi, JS | 1 |
| Soares, IS | 1 |
| da Cunha, MG | 1 |
| Silva, MN | 1 |
| Souza, JM | 1 |
| Del Portillo, HA | 1 |
| Rodrigues, MM | 1 |
| Heppner, DG | 1 |
| Tang, DB | 1 |
| Brewer, TG | 1 |
| Chokejindachai, W | 1 |
| Viriyavejakul, P | 3 |
| Milhous, WK | 1 |
| Schuster, BG | 1 |
| Horton, J | 1 |
| Braitman, DJ | 1 |
| Brueckner, RP | 1 |
| Krudsood, S | 2 |
| Treeprasertsuk, S | 1 |
| Bussaratid, V | 1 |
| Chokjindachai, W | 1 |
| Walsh D, S | 1 |
| White, J | 1 |
| Parola, P | 1 |
| Ali, I | 1 |
| Djermakoye, F | 1 |
| Crassard, N | 1 |
| Bendavid, C | 1 |
| Faugère, B | 1 |
| Condomines, P | 1 |
| Hernandez, JE | 1 |
| Nettel, JA | 1 |
| Villarreal, C | 1 |
| Wirtz, RA | 1 |
| Lopez, C | 1 |
| Oliver, M | 1 |
| Olavarria, R | 1 |
| Sarabia, MA | 1 |
| Chopite, M | 1 |
| van Gompel, A | 1 |
| Taelman, H | 1 |
| Vanham, G | 1 |
| Vervoort, T | 1 |
| Gogtay, NJ | 1 |
| Desai, S | 1 |
| Kadam, VS | 1 |
| Kamtekar, KD | 1 |
| Dalvi, SS | 1 |
| Kshirsagar, NA | 1 |
| Kroeger, A | 1 |
| Nicolas, X | 1 |
| Granier, H | 1 |
| Martin, J | 1 |
| Klotz, F | 1 |
| Ibrahim, AM | 1 |
| Elhag, ER | 1 |
| Mustafa, SE | 1 |
| Duarte, EC | 1 |
| Pang, LW | 1 |
| Ribeiro, LC | 1 |
| Wernsdorfer, WH | 1 |
| Kollaritsch, H | 1 |
| Wiedermann, G | 1 |
| Bustos, DG | 1 |
| Lazaro, JE | 1 |
| Gay, F | 1 |
| Pottier, A | 1 |
| Laracas, CJ | 1 |
| Traore, B | 1 |
| Diquet, B | 1 |
| Ehlers, G | 1 |
| Boell, F | 1 |
| Chakrapani, KP | 1 |
| Dhinagaran, D | 1 |
| Sitaraman, NL | 1 |
| Ghosh, RB | 1 |
| Saint-Yves, IF | 1 |
| Kean, BH | 2 |
| Miller, LH | 2 |
| Neva, FA | 2 |
| Gill, F | 1 |
| Dondero, TJ | 1 |
| Parsons, RE | 1 |
| O'Holohan, DR | 1 |
| Young, MD | 1 |
| Baerg, DC | 1 |
| Sandosham, AA | 1 |
| Fredericks, HJ | 1 |
| Ponnampalam, JT | 1 |
| Seow, CL | 1 |
| Ismail, O | 1 |
| Othman, AM | 1 |
| Ali, AR | 1 |
| Jenkinson, SG | 1 |
| Hargrove, MD | 1 |
| Kowertz, MJ | 1 |
| Kansky, A | 1 |
| Pandya, AP | 1 |
| Barkakaty, BN | 1 |
| Narasimham, MV | 1 |
| Froude, JR | 1 |
| Weiss, LM | 1 |
| Tanowitz, HB | 1 |
| Wittner, M | 1 |
| Basco, LK | 1 |
| Le Bras, J | 1 |
| Gillotin, C | 1 |
| Rabenjarson, E | 1 |
| Gimenez, F | 1 |
| Bouchaud, O | 1 |
| Farinotti, R | 1 |
| Coulaud, JP | 1 |
| Brewster, DR | 1 |
| Kwiatkowski, D | 1 |
| Collignon, P | 1 |
| Puri, SK | 2 |
| Sharma, P | 1 |
| Maheshwari, RK | 1 |
| Srikantan, V | 1 |
| Bhartiya, D | 1 |
| Dhawan, BN | 1 |
| Joffe, A | 1 |
| Jadavji, T | 1 |
| Tanabe, K | 2 |
| Shimada, K | 1 |
| Sharma, RC | 1 |
| Gautam, AS | 1 |
| Orlov, V | 1 |
| Skinner, JC | 1 |
| Filipski, VK | 1 |
| Broderson, JR | 1 |
| Stanfill, PS | 1 |
| Egger, B | 1 |
| Goerz, G | 1 |
| Fröscher, W | 1 |
| Hägele, H | 1 |
| Sinha, S | 1 |
| Wang, ZM | 1 |
| He, YZ | 1 |
| Huang, Z | 1 |
| Li, QJ | 2 |
| Tang, LY | 1 |
| Zhang, XJ | 1 |
| Pang, LL | 1 |
| Yang, BL | 3 |
| Wang, WJ | 1 |
| Yuan, HA | 1 |
| Zhu, FH | 1 |
| Liu, WJ | 1 |
| Chittamas, S | 1 |
| Bunnag, D | 1 |
| Harinasuta, T | 3 |
| Wirima, J | 1 |
| Khoromana, C | 1 |
| Molyneux, ME | 1 |
| Gilles, HM | 1 |
| Gouet, D | 1 |
| Maréchaud, R | 1 |
| Le Berre, D | 1 |
| Alcalay, M | 1 |
| Becq-Giraudon, B | 1 |
| Boissonnot, L | 1 |
| Bontoux, D | 1 |
| Gil, R | 1 |
| Lefevre, JP | 1 |
| Risse, JF | 1 |
| McGlone, R | 1 |
| Mulik, R | 1 |
| Richardson, MR | 1 |
| Zalin, AM | 1 |
| Ohtomo, H | 1 |
| Hioki, A | 1 |
| Nakabayashi, T | 1 |
| Ishizaki, T | 1 |
| Kabiru, EW | 1 |
| Gachare, JW | 1 |
| Mbaabu, DA | 1 |
| Ngindu, AM | 1 |
| Siongok, TK | 1 |
| De Waele, C | 1 |
| Manach, Y | 1 |
| Florant, A | 1 |
| Perrin, A | 1 |
| Johns, CJ | 1 |
| Schonfeld, SA | 1 |
| Scott, PP | 1 |
| Zachary, JB | 1 |
| MacGregor, MI | 1 |
| Wan, WJ | 1 |
| Wang, WR | 1 |
| Hu, HX | 1 |
| Li, HX | 1 |
| Li, XL | 1 |
| Li, CZ | 1 |
| Huang, GZ | 1 |
| Schmidt, LH | 1 |
| Wang, XX | 1 |
| Zhong, YX | 1 |
| Deng, BS | 1 |
| Springer, C | 1 |
| Maayan, C | 1 |
| Katzir, Z | 1 |
| Ariel, I | 1 |
| Godfrey, S | 1 |
| Chen, KY | 1 |
| Shao, BR | 1 |
| Glew, RH | 1 |
| Howard, WA | 2 |
| Wyler, DJ | 1 |
| Chaves-Carballo, E | 1 |
| Warren, M | 1 |
| Powers, G | 1 |
| Garnham, PC | 1 |
| Shiroishi, T | 1 |
| Dioguardi, N | 1 |
| Singh, I | 1 |
| Lal, M | 1 |
| Nanda, RB | 1 |
| Kumar, BR | 1 |
| Reuschel, I | 1 |
| Reinelt, D | 1 |
| Gruber, G | 1 |
| Reed, WB | 1 |
| Bergeron, RF | 1 |
| Tuffanelli, D | 1 |
| Jones, EW | 1 |
| Charoenlarp, P | 1 |
| Chin, W | 3 |
| Rattanarithikul, M | 1 |
| Contacos, PG | 2 |
| Jeter, MH | 1 |
| Briesch, PE | 1 |
| Weise, HJ | 1 |
| Mirić, V | 1 |
| Tomasević, M | 1 |
| Barrett-Connor, E | 1 |
| Jaroonvesama, N | 1 |
| Munangmanee, L | 1 |
| Krotoski, WA | 1 |
| Knüttgen, H | 1 |
| Kövesi, G | 1 |
| Rieckmann, KH | 2 |
| Powell, RD | 3 |
| McNamara, JV | 3 |
| Willerson, D | 1 |
| Lass, L | 1 |
| Frischer, H | 2 |
| Carson, PE | 2 |
| Stockert, TA | 1 |
| DeGowin, RL | 1 |
| Bruce-Chwatt, LJ | 1 |
| Taljaard, JJ | 1 |
| Shanley, BC | 1 |
| Stewart-Wynne, EG | 1 |
| Deppe, WM | 1 |
| Joubert, SM | 1 |
| Coatney, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria[NCT02563496] | Phase 2 | 60 participants (Actual) | Interventional | 2017-02-06 | Completed | ||
| Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil[NCT03610399] | 257 participants (Actual) | Interventional | 2018-04-09 | Completed | |||
| Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934] | Phase 4 | 524 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905] | Phase 3 | 655 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax[NCT01640574] | Phase 3 | 680 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico[NCT02394197] | Phase 4 | 153 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria[NCT01378286] | Phase 3 | 380 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan[NCT00682578] | Phase 3 | 1,086 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095] | Early Phase 1 | 18 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites[NCT01082341] | Phase 1/Phase 2 | 27 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood samples were collected at indicated time points for pharmacokinetic analysis of tafenoquine. Pharmacokinetic parameters were determined using standard non-compartmental methods. AUC(0-infinity) of tafenoquine was evaluated for participants aged >=2 years to <16 years (weighing >=5 kg). Pharmacokinetic (PK) population consisted of all participants with at least one PK sample taken at Days 3, 15, 29 and 60, with accurate dosing and sample time histories. (NCT02563496)
Timeframe: Days 3, 15, 29 and 60 post dose
| Intervention | Hours*microgram per milliliter (Median) |
|---|---|
| Tafenoquine 100 mg | 85.1 |
| Tafenoquine 150 mg | 154.7 |
| Tafenoquine 200 mg | 111.4 |
| Tafenoquine 300 mg | 120.8 |
Relapse is defined as positive blood smear with or without vivax malaria symptoms. A participant was considered to have demonstrated relapse-free efficacy if: a) Participant is slide positive for Plasmodium vivax (P. vivax) at Baseline. b) Participant showed initial clearance of P. vivax parasitemia defined as a negative slide at or before the Day 29 visit. c) Participant is not slide-positive for P. vivax at any assessment. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 4 months defined as a negative asexual P. vivax parasite slide at the first parasite assessment performed during study. Microbiologic-Intent-To-Treat (mITT) Population consisted of all participants who received a dose of study treatment (tafenoquine) and had microscopically-confirmed vivax parasitemia at Baseline. (NCT02563496)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tafenoquine 100 mg | 12 |
| Tafenoquine 150 mg | 4 |
| Tafenoquine 200 mg | 20 |
| Tafenoquine 300 mg | 17 |
Number of participants experiencing gastrointestinal adverse events including vomiting, abdominal pain, diarrhea, gastrointestinal disorder, epigastric discomfort and nausea were assessed. Number of participants with gastrointestinal adverse events for each treatment group have been presented. Safety Population consisted of all participants who received at least one dose of study medication (tafenoquine). (NCT02563496)
Timeframe: Up to Day 120
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Vomiting | Abdominal pain | Diarrhea | Gastrointestinal disorder | Epigastric discomfort | Nausea | |
| Tafenoquine 100 mg | 2 | 0 | 2 | 0 | 0 | 0 |
| Tafenoquine 150 mg | 3 | 0 | 0 | 1 | 0 | 0 |
| Tafenoquine 200 mg | 1 | 3 | 1 | 1 | 0 | 0 |
| Tafenoquine 300 mg | 6 | 0 | 0 | 0 | 1 | 1 |
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines. Blood samples were collected for the evaluation of hemoglobin levels. Hemoglobin decrease of >=30 percent (%) of >30 grams per liter (g/L) from Baseline; or, an overall drop in hemoglobin below 60.0 g/L in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs). Number of participants with hemoglobin decline from Baseline over first 10 days have been presented. Baseline was defined as the latest pre-tafenoquine dose assessment on Day 1. (NCT02563496)
Timeframe: Baseline and up to Day 10
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| <=20 g/L | >20 g/L to <=30 g/L | >30 g/L or >=30% | |
| Tafenoquine 100 mg | 14 | 0 | 0 |
| Tafenoquine 150 mg | 5 | 0 | 0 |
| Tafenoquine 200 mg | 21 | 1 | 0 |
| Tafenoquine 300 mg | 19 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury. (NCT02563496)
Timeframe: Up to Day 120
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Non-SAEs | SAEs | |
| Tafenoquine 100 mg | 10 | 0 |
| Tafenoquine 150 mg | 4 | 0 |
| Tafenoquine 200 mg | 10 | 0 |
| Tafenoquine 300 mg | 13 | 1 |
"Blood samples were collected for analysis of clinical chemistry parameters. PCI ranges were >3*ULN international units per liter (IU/L) (alanine aminotransferase [ALT]), >2.5*ULN IU/L (alkaline phosphatase), >3*ULN IU/L (aspartate aminotransferase [AST]), >1.5*ULN micromoles/L (mcmol/L) (bilirubin), >5*ULN IU/L (creatine kinase [CK]), 3*ULN mcmol/L (creatinine), >1.5*ULN mcmol/L (indirect bilirubin), and >11.067 millimoles/L (urea). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline value is the latest pre-Tafenoquine dose assessment on Day 1." (NCT02563496)
Timeframe: Baseline (Day 1) and up to Day 8
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: To Low | ALT: To within Range or No Change | ALT: To High | Alkaline phosphatase: To Low | Alkaline phosphatase: To within Range or No Change | Alkaline phosphatase: To High | AST: To Low | AST: To within Range or No Change | AST: To High | Bilirubin: To Low | Bilirubin: To within Range or No Change | Bilirubin: To High | CK: To Low | CK: To within Range or No Change | CK: To High | Creatinine: To Low | Creatinine: To within Range or No Change | Creatinine: To High | Indirect bilirubin: To Low | Indirect bilirubin: To within Range or No Change | Indirect bilirubin: To High | Urea: To Low | Urea: To within Range or No Change | Urea: To High | |
| Tafenoquine 100 mg | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 14 | 0 |
| Tafenoquine 150 mg | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 |
| Tafenoquine 200 mg | 0 | 22 | 0 | 0 | 21 | 1 | 0 | 22 | 0 | 0 | 22 | 0 | 0 | 22 | 0 | 0 | 22 | 0 | 0 | 22 | 0 | 0 | 22 | 0 |
| Tafenoquine 300 mg | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 | 0 | 19 | 0 |
"Blood samples were collected for analysis of eosinophils, lymphocytes, platelets and reticulocytes. PCI ranges were >1.5*10^9 (high) cells per liter (cells/L) for eosinophils, <0.5*10^9 cells/L (low) or >4*10^9 cells/L (high) for lymphocytes, <50*10^9 cells/L (low) for platelet count and >1*upper limit of normal (ULN) 10^12 cells/L (high) for reticulocyte count. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline value is the latest pre-tafenoquine dose assessment on Day 1." (NCT02563496)
Timeframe: Baseline (Day 1) and up to Day 8
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eosinophils: To Low | Eosinophils: To within Range or No Change | Eosinophils: To High | Lymphocytes: To Low | Lymphocytes: To within Range or No Change | Lymphocytes: To High | Platelet count: To Low | Platelet count: To within Range or No Change | Platelet count: To High | Reticulocyte count: To Low | Reticulocyte count: To within Range or No Change | Reticulocyte count: To High | |
| Tafenoquine 100 mg | 0 | 12 | 2 | 0 | 9 | 5 | 0 | 14 | 0 | 0 | 13 | 1 |
| Tafenoquine 150 mg | 0 | 4 | 1 | 0 | 3 | 2 | 0 | 5 | 0 | 0 | 5 | 0 |
| Tafenoquine 200 mg | 0 | 20 | 2 | 0 | 20 | 2 | 0 | 22 | 0 | 0 | 18 | 4 |
| Tafenoquine 300 mg | 0 | 18 | 1 | 0 | 16 | 3 | 0 | 19 | 0 | 0 | 15 | 4 |
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 168 days
| Intervention | participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 29 |
| Primaquine Regular Dose Supervised | 44 |
| Primaquine Double Dose Unsupervised | 67 |
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 61 |
| Primaquine Regular Dose Supervised | 88 |
| Primaquine Double Dose Unsupervised | 90 |
Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites. (NCT03610399)
Timeframe: 168 days
| Intervention | Participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 29 |
| Primaquine Regular Dose Supervised | 44 |
| Primaquine Double Dose Unsupervised | 67 |
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
| Intervention | days (Mean) |
|---|---|
| Group 1 | 11 |
| Group 2 | 11 |
| Group 3 | 9 |
10 reviews available for chloroquine and Recrudescence
| Article | Year |
|---|---|
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D | 2020 |
Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.
Topics: Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Ma | 2018 |
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 2018 |
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.
Topics: Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Global Health; Humans; Malar | 2014 |
Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Administration Schedule; Humans; Malaria, | 2015 |
Chloroquine resistance in Plasmodium vivax.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Recu | 2004 |
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Malaria, Vivax; Male; Plasmodi | 1997 |
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans; | 2000 |
Neurological sequelae of cerebral malaria in children.
Topics: Adolescent; Animals; Antimalarials; Brain Diseases; Child; Chloroquine; Coma; Follow-Up Studies; Gam | 1990 |
[Importation of malaria into the Federal Republic of Germany including Berlin (West) in the last ten years (1963-1972)].
Topics: Africa; Age Factors; Aircraft; Amodiaquine; Antimalarials; Asia; Berlin; Chloroquine; Disease Outbre | 1974 |
45 trials available for chloroquine and Recrudescence
| Article | Year |
|---|---|
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; | 2022 |
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; | 2022 |
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; | 2022 |
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; | 2022 |
Higher-Dose Primaquine to Prevent Relapse of
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Directly Obser | 2022 |
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho | 2017 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc | 2014 |
Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dia | 2015 |
Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Brazil; Child; Child, Preschool; | 2017 |
A trial of combination antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Therapy, Co | 2008 |
Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Fe | 2010 |
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
Topics: Adolescent; Afghanistan; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Adm | 2010 |
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Ethiopia; Female; Humans; In | 2011 |
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Female; Humans | 2011 |
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Female; Genotype; Genotyping Techniq | 2012 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Chloroquine for the treatment of uncomplicated malaria in Guyana.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Follow-Up St | 2002 |
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Topics: Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Incidence; Indonesia; Malaria, Falcip | 2002 |
The efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria in Laos.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Fema | 2002 |
A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Administration, Oral; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, | 2003 |
Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc | 2004 |
Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschoo | 2004 |
Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Female; Humans; Infant; Malaria, Falcip | 2006 |
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Child, Preschool; Chloroq | 2007 |
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; Humans; India; Malaria, | 2007 |
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].
Topics: Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Clinical Pro | 2007 |
Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.
Topics: Adolescent; Amodiaquine; Blood; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; F | 1984 |
A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda.
Topics: Adult; Aged; Bloodletting; Chloroquine; Female; Humans; Liver; Male; Middle Aged; Porphyrias; Recurr | 1981 |
[Comparative evaluation of the therapeutic effectiveness of small and regular doses of delagil in porphyria cutanea tarda].
Topics: Adult; Aged; Chloroquine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male; Middle | 1981 |
Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
Topics: Adolescent; Adult; Aged; Child; Chloroquine; Drug Therapy, Combination; Female; Germany; Humans; Mal | 1995 |
Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload.
Topics: Administration, Oral; Adult; Aged; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Ir | 1994 |
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Follow-Up Studi | 1994 |
Curing of chloroquine-resistant malaria with clindamycin.
Topics: Adolescent; Adult; Aged; Animals; Chloroquine; Clindamycin; Drug Resistance; Female; Follow-Up Studi | 1993 |
Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Chloroqui | 1995 |
Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimalarials; Chloroquine; Drug Therapy, Combination; Fev | 1996 |
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia; | 1997 |
In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Hum | 1997 |
Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children.
Topics: Acute Disease; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chil | 1998 |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Dr | 1999 |
Chloroquine sensitivity of Plasmodium vivax in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Mala | 1999 |
Ketotifen in treatment of uncomplicated falciparum malaria.
Topics: Adult; Antimalarials; Body Weight; Chloroquine; Drug Monitoring; Drug Therapy, Combination; Follow-U | 2000 |
In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance.
Topics: Adult; Animals; Antimalarials; Artemisinins; Chloroquine; Cross Reactions; Drug Resistance; Drug The | 2001 |
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combi | 2002 |
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Area Under Curve; Child; Chloroquine; Drug Administ | 2002 |
Clinical trials with halofantrine hydrochloride in Malawi.
Topics: Administration, Oral; Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Clin | 1988 |
Combined chloroquine-primaquine therapy against vivax malaria.
Topics: Chloroquine; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Malaria; Plasmodium vivax | 1974 |
[Follow-up of a course of intermittent rheumatism].
Topics: Adult; Aspirin; Chloroquine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrarthro | 1974 |
152 other studies available for chloroquine and Recrudescence
| Article | Year |
|---|---|
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals | 2009 |
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Cytochrome P-450 CYP2D6; Ghana; Humans; Inacti | 2019 |
Plasmodium vivax exflagellated microgametes in human peripheral blood: a potential diagnostic dilemma.
Topics: Adult; Animals; Chloroquine; Humans; Life Cycle Stages; Malaria, Vivax; Male; Plasmodium vivax; Recu | 2019 |
Targeting redox heterogeneity to counteract drug tolerance in replicating
Topics: Acids; Animals; Antitubercular Agents; Bacterial Proteins; Chloroquine; Cysteine; Drug Interactions; | 2019 |
Cost-Effectiveness Analysis of Sex-Stratified
Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Ana | 2020 |
ASSESSMENT OF THE EFFICACY AND SAFETY OF CHLOROQUINE MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED GESTATIONAL MALARIA CAUSED BY
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Chloroquine; Colombia; Drug Evaluation; Female; Fol | 2020 |
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans; | 2020 |
Short-Time Recurrences of
Topics: Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Humans; Malaria, Vivax; Public Health; | 2021 |
Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Vivax; Male; Middle A | 2021 |
Recrudescing Plasmodium malariae infection despite appropriate treatment in an immigrant toddler.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Atovaquone; Chloroquine; Communicable Dise | 2018 |
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cytochrome P-450 CYP | 2018 |
Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Cambodia; Chloroquine; Drug Resistance; Female; Genotype; Humans; | 2019 |
A 38-year-old man with fever and a history of malaria.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Malaria, Vivax; Male; Pri | 2018 |
Evaluation of Plasmodium vivax malaria recurrence in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Brazil; Child; Child, Presc | 2019 |
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Drug Therapy, Combination; Female; F | 2019 |
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia.
Topics: Adolescent; Adult; Antimalarials; Body Temperature; Child; Child, Preschool; Chloroquine; Ethiopia; | 2019 |
Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule | 2019 |
Effective treatment with a tetrandrine/chloroquine combination for chloroquine-resistant falciparum malaria in Aotus monkeys.
Topics: Administration, Oral; Animals; Antimalarials; Aotus trivirgatus; Benzylisoquinolines; Chloroquine; D | 2013 |
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Drug Tolerance; Genome, Protozoan; High-Throug | 2013 |
Imported malaria is stable from Africa but declining from Asia.
Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre | 2014 |
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini | 2014 |
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther | 2014 |
Interactive medical case. A chilly fever.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Life Cycle Stages; Malari | 2014 |
Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Male; | 2015 |
[13-year old girl with fever 6 months after returning from sub-Saharan Africa].
Topics: Adolescent; Africa; Chloroquine; Developing Countries; Female; Fever of Unknown Origin; Germany; Hum | 2015 |
Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy, | 2016 |
Recrudescence of
Topics: Administration, Intravenous; Adult; Antimalarials; Chemoprevention; Chloroquine; Female; Gravidity; | 2017 |
Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Ethiopia; Female; Hematocrit; Humans; Infant; M | 2017 |
Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquin | 2008 |
Transmission of different strains of Plasmodium cynomolgi to Aotus nancymaae monkeys and relapse.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Insect Vectors; Malaria; Monkey Diseases; P | 2009 |
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood; Child; Child, Preschool; Chloroquine; Chromatograp | 2008 |
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype | 2009 |
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood Chemical Analysis; Child; Child, Preschool; Chloroq | 2009 |
Cardiotoxicity after low-dose chloroquine antimalarial therapy.
Topics: Administration, Oral; Antimalarials; Biopsy; Chloroquine; Heart Failure; Heart Ventricles; Humans; M | 2009 |
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
Topics: Animals; Antimalarials; Chloroquine; Cohort Studies; Female; Follow-Up Studies; French Guiana; Human | 2009 |
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi | 2009 |
Case report: An unusual late relapse of Plasmodium vivax malaria.
Topics: Animals; Antimalarials; Chloroquine; Diagnosis, Differential; DNA, Protozoan; Drug Administration Sc | 2003 |
Prevalence of malaria in Aligarh.
Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India; | 2002 |
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; Indonesia; Life Tabl | 2003 |
Asymptomatic, recrudescent, chloroquine-resistant Plasmodium falciparum infections in Nigerian children: clinical and parasitological characteristics and implications for the transmission of drug-resistant parasites.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Fe | 2003 |
[Plasmodium berghei in mice; appearance of a state of immunity following repeated treatments with nivaquine during relapse].
Topics: Animals; Chloroquine; Chronic Disease; Immunity; Malaria; Mice; Plasmodium berghei; Quinolines; Recu | 1954 |
Relapses with Chesson strain Plasmodium vivax following treatment with chloroquine.
Topics: Chloroquine; Hyperthermia, Induced; Neurosyphilis; Plasmodium vivax; Recurrence | 1956 |
Relapses of porphyria induced by chloroquine (aralen) phosphate; report of a case.
Topics: Chloroquine; Humans; Minnesota; Phosphates; Porphyrias; Recurrence | 1960 |
Chloroquine-resistant Plasmodium vivax malaria in Peru.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; DNA, Protozoan; Dru | 2003 |
Multi-drug resistant Plasmodium falciparum malaria in Assam, India: timing of recurrence and anti-malarial drug concentrations in whole blood.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance, Multiple; Female; Hu | 2003 |
Molecular analysis of Plasmodium falciparum recrudescent malaria infections in children treated with chloroquine in Nigeria.
Topics: Animals; Antigens, Protozoan; Antimalarials; Child; Child, Preschool; Chloroquine; DNA, Protozoan; D | 2004 |
Plasmodium yoelii: influence of antimalarial treatment on acquisition of immunity in BALB/c and DBA/2 mice.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Immuno | 2007 |
Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Humans; Malaria, Vivax; Recurrence | 2007 |
Positive impact of chloroquine on delayed pressure urticaria.
Topics: Adult; Amebicides; Antimalarials; Antirheumatic Agents; Chloroquine; Humans; Male; Pressure; Recurre | 2007 |
Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antimalarials; Chemical and Drug Induced Liver | 2007 |
Apparent relapse of imported Plasmodium ovale malaria in a pregnant woman.
Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria; Plasmodium ovale; Pregnancy; Pr | 2007 |
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; G | 2008 |
Possible role of drug malabsorption in recrudescence of falciparum malaria.
Topics: Chloroquine; Humans; Malaria; Male; Middle Aged; Plasmodium falciparum; Recurrence; United Kingdom; | 1982 |
[Relapses and indirect fluorescent antibody level in vivax malaria patients after chloroquine and chloroquine-primaquine treatment].
Topics: Antibodies; Chloroquine; Fluorescent Antibody Technique; Humans; Malaria; Plasmodium vivax; Primaqui | 1984 |
Results of 3-day radical treatment of Plasmodium vivax in North Arcot and South Arcot Districts of Tamil Nadu.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; Humans; | 1984 |
Low-dose oral chloroquine in the treatment of porphyria cutanea tarda.
Topics: Administration, Oral; Adult; Aged; Chloroquine; Drug Administration Schedule; Humans; Male; Middle A | 1984 |
Influence of progesterone and estrogen administration on the recrudescence patterns of Plasmodium knowlesi infection in female rhesus monkeys (Macaca mulatta) following initial subcurative chloroquine therapy.
Topics: Animals; Antibody Formation; Chloroquine; Estrogens; Female; Immune Tolerance; Macaca mulatta; Malar | 1984 |
Chemotherapy, relapses and CNS in experimental African trypanosomiasis.
Topics: Animals; Central Nervous System; Chlorocebus aethiops; Chloroquine; Melarsoprol; Mice; Recurrence; T | 1983 |
Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy.
Topics: Adult; Aged; Bloodletting; Chloroquine; Female; Follow-Up Studies; Humans; Liver; Male; Middle Aged; | 1982 |
An analysis of the relationship of host factors to clinical falciparum malaria by multiple regression techniques.
Topics: Adult; Age Factors; Black People; Body Weight; Chloroquine; Clindamycin; Fever; Humans; Malaria; Mal | 1982 |
[Prevention of recurrence of malaria with primaquine].
Topics: Adult; Child; Child, Preschool; Chloroquine; Follow-Up Studies; Humans; Malaria; Male; Middle Aged; | 1982 |
[Inadequate effect of malaria prevention].
Topics: Chloroquine; Denmark; Female; Guinea-Bissau; Humans; Malaria; Male; Proguanil; Recurrence | 1980 |
[Erythema elevatum diutinum].
Topics: Aged; Chloroquine; Erythema; Female; Humans; Recurrence | 1980 |
Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India.
Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Prim | 1995 |
Subclinical avian malaria infections in African black-footed penguins (Spheniscus demersus) and induction of parasite recrudescence.
Topics: Animals; Animals, Zoo; Baltimore; Birds; Chloroquine; Dexamethasone; Ducks; Immunosuppression Therap | 1994 |
[Studies on the establishment of malarial animal model of short-term relapse. IV. Short-term relapse in rhesus monkeys infected with sporozoites of Plasmodium cynomolgi].
Topics: Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Disease Models, Animal; Drug Therapy, | 1993 |
[Difficulties of diagnosis and treatment of malaria outbreaks in Europeans living in Burkina Faso].
Topics: Adult; Burkina Faso; Child, Preschool; Chloroquine; Drug Resistance; Europe; Humans; Infant; Malaria | 1993 |
[Studies on the establishment of malarial animal model of short-term relapse. III. Combined therapy with pyronaridine-artemether-chloroquine for parasitemia clearance].
Topics: Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Disease Models, Animal; Drug Therapy, | 1993 |
[Reactivation of hepatitis B following withdrawal of chloroquine].
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Female; Hepatitis B; Hepatitis B Core Antigens; Hepatitis | 1994 |
Curative efficacy of norfloxacin in falciparum malaria.
Topics: Adolescent; Adult; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria, Falciparum; M | 1993 |
Canadian recommendations for the prevention and treatment of malaria among international travellers. Committee to Advise on Tropical Medicine and Travel (CATMAT).
Topics: Animals; Antimalarials; Canada; Child; Chloroquine; Culicidae; Drug Resistance; Female; Humans; Mala | 1995 |
Resurgence of malaria and drug resistance in Plasmodium falciparum and vivax species in Bombay.
Topics: Antimalarials; Chloroquine; Drug Resistance; Follow-Up Studies; Humans; India; Malaria, Falciparum; | 1996 |
Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1996 |
Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1997 |
Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; F | 1996 |
Chloroquine--induced recurrent psychosis (brief report).
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Dose-Response Relationship, Drug; Female; Human | 1996 |
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist | 1997 |
[In vivo chemosensitivity tests of Plasmodium falciparum to chloroquine in Senegal: the development of resistance and the assessment of therapeutic efficacy].
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Animals; Antimalarials; Bias; Chemop | 1997 |
Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations.
Topics: Afghanistan; Antimalarials; Chloroquine; Drug Resistance; Humans; Incidence; Insect Control; Malaria | 1997 |
Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; C | 1996 |
Primaquine-tolerant vivax malaria in Thailand.
Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu | 1997 |
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models, | 1998 |
Is chronic ulcerative stomatitis an entity? Clinical and immunological findings in 18 cases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antinuclear; Antimalarials; Chloroquine; Chronic Disease | 1998 |
Imported tertian malaria resistant to primaquine.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Pla | 1999 |
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1.
Topics: Adult; Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Enzyme-Linked Immunosorbe | 1999 |
[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1999 |
Different prevalences of Plasmodium vivax phenotypes VK210 and VK247 associated with the distribution of Anopheles albimanus and Anopheles pseudopunctipennis in Mexico.
Topics: Altitude; Animals; Anopheles; Antibodies, Monoclonal; Antibodies, Protozoan; Antimalarials; Chloroqu | 2000 |
Relapsing vivax malaria, chloroquine toxicity, anxiety, or alcohol misuse?
Topics: Alcoholism; Animals; Antimalarials; Anxiety; Chloroquine; Diagnosis, Differential; Humans; Malaria, | 2000 |
Kikuchi-Fujimoto necrotizing lymphadenitis associated with cutaneous lupus erythematosus: a case report.
Topics: Adult; Antirheumatic Agents; Chloroquine; Female; Histiocytic Necrotizing Lymphadenitis; Humans; Lup | 2000 |
Hyperreactive malaria in expatriates returning from sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Animals; Antibodies, Protozoan; Antimalarials; | 2000 |
Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
Topics: Adolescent; Adult; Age Distribution; Aged; Animals; Antimalarials; Chloroquine; Female; Follow-Up St | 2000 |
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria, | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
[Leishmaniasis cutanes recidivans. Report of a case].
Topics: Adult; Biopsy; Chloroquine; Chronic Disease; Dihydrostreptomycin Sulfate; Humans; Leishmaniasis, Muc | 1975 |
Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu.
Topics: Adult; Child; Chloroquine; Follow-Up Studies; Humans; India; Malaria; Plasmodium vivax; Primaquine; | 1977 |
Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands.
Topics: Adolescent; Adult; Child; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria; Male; | 1977 |
Chloroquine-resistant falciparum malaria from Africa.
Topics: Adult; Africa; Chloroquine; Drug Resistance; Humans; Malaria; Male; Plasmodium falciparum; Recurrenc | 1979 |
Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters.
Topics: Animals; Babesiosis; Benzamidines; Chloroquine; Cricetinae; Drug Resistance; Humans; Male; Metronida | 1978 |
Increased frequency of chloroquine resistant P. falciparum on a rubber estate in Peninsular Malaysia during two years of systematic chloroquine treatment.
Topics: Blood; Chloroquine; Drug Resistance, Microbial; Humans; Longitudinal Studies; Malaria; Malaysia; Pla | 1975 |
Chemotherapy of Plasmodium vivax in Saimiri and Aotus models.
Topics: Administration, Oral; Animals; Chloroquine; Disease Models, Animal; Drug Combinations; Drug Evaluati | 1975 |
Chloroquine resistant malaria in West Malaysia.
Topics: Anopheles; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Malaysia; Plasmodium falciparum | 1975 |
The treatment of amebiasis. A recurrent agony.
Topics: Amebiasis; Amebicides; Chloroquine; Drug Therapy, Combination; Dysentery, Amebic; Emetine; Humans; I | 1976 |
Recurrent amebic abscess of the liver.
Topics: Adult; Antibody Formation; Biopsy, Needle; Chloroquine; Emetine; Humans; Liver Abscess, Amebic; Male | 1975 |
Letter: Retreatment with chloroquine in porphyria cutanea tarda.
Topics: Administration, Oral; Chloroquine; Humans; Porphyrias; Recurrence | 1975 |
[Disseminated granuloma annulare].
Topics: Arm; Buttocks; Chloroquine; Ear, External; Granuloma; Humans; Male; Middle Aged; Prednisone; Recurre | 1975 |
Importance of mean parasite clearance time and recrudescence time and their role in gradation of Plasmodium falciparum resistance.
Topics: Adolescent; Adult; Age Factors; Animals; Child; Child, Preschool; Chloroquine; Drug Evaluation; Drug | 1992 |
Imported malaria in the Bronx: review of 51 cases recorded from 1986 to 1991.
Topics: Adolescent; Adult; Africa, Western; Animals; Antimalarials; Asia, Western; Chi-Square Distribution; | 1992 |
Type RI resistance to halofantrine in West Africa.
Topics: Animals; Antimalarials; Biological Availability; Chloroquine; Cote d'Ivoire; Drug Resistance; Follow | 1991 |
Chloroquine resistance in Plasmodium vivax.
Topics: Animals; Chloroquine; Drug Resistance; Humans; Malaria; Male; Plasmodium vivax; Recurrence | 1991 |
Pattern of relapses in sporozoite induced Plasmodium cynomolgi B infection in rhesus monkeys.
Topics: Animals; Chloroquine; Disease Models, Animal; Macaca mulatta; Malaria; Recurrence; Time Factors | 1990 |
Effects of interferon in malaria infection.
Topics: Animals; Antiviral Agents; Chloroquine; Female; Interferon Type I; Interferon-gamma; Macaca mulatta; | 1990 |
Congenital malaria: a case report of a preventable disease.
Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Infant, Newborn; Malaria; Male; Plasmodi | 1990 |
[Clinical evaluation of antimalarial drugs].
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Evaluation; Female; Humans; Malaria; Male; Plasmodi | 1990 |
Relapse pattern of Plasmodium vivax in Kheda district, Gujarat.
Topics: Animals; Chloroquine; Drug Therapy, Combination; Humans; India; Malaria; Plasmodium vivax; Primaquin | 1990 |
The Peruvian III strain of Plasmodium brasilianum in Saimiri sciureus boliviensis monkeys.
Topics: Animals; Anopheles; Chloroquine; Malaria; Mefloquine; Monkey Diseases; Recurrence; Saimiri | 1990 |
[Artefacts in porphyria cutanea tarda].
Topics: Bloodletting; Chloroquine; Combined Modality Therapy; Diagnosis, Differential; Humans; Male; Malinge | 1990 |
[Suspected convulsion-inducing effect of chloroquine (Resochin)].
Topics: Adult; Chloroquine; Epilepsies, Partial; Female; Humans; Malaria; Recurrence | 1989 |
Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.).
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria; M | 1989 |
[Experimental studies on the incubation period and relapse patterns in vivax malaria in west Hunan].
Topics: Animals; Chloroquine; Humans; Malaria; Plasmodium vivax; Recurrence | 1989 |
[Field observation on the relapse pattern in patients naturally infected with vivax malaria from spring to autumn seasons in Cili County, Hunan Province].
Topics: Animals; Antimalarials; Chloroquine; Humans; Malaria; Plasmodium vivax; Recurrence; Seasons | 1989 |
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimalarials; Chloroquine; Female; Follow-Up Studies; Hu | 1987 |
[Prognosis of treated temporal arteritis. Retrospective study of 87 cases].
Topics: Aged; Chloroquine; Cyclophosphamide; Dapsone; Drug Therapy, Combination; Female; Giant Cell Arteriti | 1986 |
Hypnozoites in Bradford.
Topics: Animals; Child, Preschool; Chloroquine; England; Fever; Humans; Infant, Newborn; Malaria; Male; Plas | 1988 |
Treatment of palindromic rheumatism with chloroquine.
Topics: Adult; Chloroquine; Humans; Male; Middle Aged; Recurrence; Rheumatic Diseases | 1987 |
Clinical evaluation of antimalarial regimens in Japan.
Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Japan; Malaria; Plasmodium f | 1987 |
In-vivo falciparum malaria response to chloroquine in Kisumu-Kenya.
Topics: Adolescent; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Kenya; M | 1987 |
[D-penicillamine in the treatment of recurrent laryngeal stenosis in children].
Topics: Child; Child, Preschool; Chloroquine; Collagen; Female; Follow-Up Studies; Humans; Intubation, Intra | 1988 |
Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.
Topics: Adult; Black People; Chloroquine; Chronic Disease; Female; Follow-Up Studies; Humans; Lung Diseases; | 1986 |
[Experimental studies on the biological characteristics of Plasmodium vivax in south Yunnan].
Topics: Animals; Anopheles; China; Chloroquine; Humans; Malaria; Plasmodium vivax; Primaquine; Recurrence | 1986 |
Compatibility of relapse patterns of Plasmodium cynomolgi infections in rhesus monkeys with continuous cyclical development and hypnozoite concepts of relapse.
Topics: Animals; Chloroquine; Female; Humans; Macaca mulatta; Malaria; Male; Pan troglodytes; Plasmodium; Pl | 1986 |
[Further studies on the relapse of Plasmodium cynomolgi in rhesus monkeys].
Topics: Animals; Chloroquine; Macaca mulatta; Malaria; Plasmodium; Recurrence | 1986 |
Chloroquine treatment in desquamative interstitial pneumonia.
Topics: Chloroquine; Humans; Infant; Male; Pulmonary Fibrosis; Recurrence | 1987 |
[Therapeutic effect of pyronaridine given intragastrically on Plasmodium cynomolgi-infected rhesus monkeys].
Topics: Animals; Antimalarials; Chloroquine; Macaca fascicularis; Macaca mulatta; Malaria; Naphthyridines; R | 1985 |
Response to treatment in man of multi-drug resistant Plasmodium falciparum from Panama.
Topics: Adult; Amodiaquine; Animals; Anopheles; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug | 1974 |
Plasmodium cynomolgi: influence of x-irradiation and sporozoite dilution on relapse patterns in infected rhesus monkeys.
Topics: Animals; Anopheles; Blood; Chloroquine; Haplorhini; Injections, Intramuscular; Macaca; Malaria; Plas | 1974 |
[The treatment of chronic hepatitis (author's transl)].
Topics: Adrenal Cortex Hormones; Antimetabolites; Azathioprine; Chloroquine; Chronic Disease; Hepatitis; Hum | 1974 |
Hepatic amoebiasis at high altitude.
Topics: Adult; Altitude; Chloroquine; Emetine; Evaluation Studies as Topic; Humans; India; Liver Abscess, Am | 1974 |
[Diagnosis and course evaluation in rheumatic fever].
Topics: Acute Disease; Adult; Aminopyrine; Child; Chloroquine; Humans; Penicillins; Phenylbutazone; Predniso | 1974 |
Hereditary inflammatory vasculitis with persistent nodules. A genetically-determined new entity probably related to lupus erythematosus.
Topics: Arteritis; Arthritis, Rheumatoid; Chloroquine; Erythema Nodosum; Female; Fibromyalgia; Humans; Lupus | 1972 |
Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase; | 1973 |
The evaluation of the presumptive and radical treatments against falciparum malaria in Thailand.
Topics: Adolescent; Adult; Blood; Chloroquine; Drug Evaluation; Female; Humans; Malaria; Male; Plasmodium fa | 1973 |
Chemoprophylaxis of malaria for travelers.
Topics: Africa; Antimalarials; Asia; Central America; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug | 1974 |
Recrudescence, poor response or resistance to quinine of falciparum malaria in Thailand.
Topics: Administration, Oral; Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Inj | 1974 |
Studies on the characterization of plasmodium vivax strains from Central America.
Topics: Animals; Central America; Chloroquine; Haplorhini; Humans; Lincomycin; Malaria; Plasmodium vivax; Pr | 1972 |
[Letter: Primary long latency in malaria].
Topics: Chloroquine; Malaria; Primaquine; Recurrence; Time Factors | 1973 |
Results obtained with delagil in the treatment of lichen oris.
Topics: Administration, Oral; Chloroquine; Female; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases; | 1974 |
Effects of tetracycline against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum.
Topics: Administration, Oral; Body Temperature; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Ma | 1971 |
Acquired decrease in sensitivity to quinine observed during studies with a strain of chloroquine-resistant Plasmodium falciparum.
Topics: Adult; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodium falciparum; Pyrime | 1967 |
Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum.
Topics: Adult; Antimalarials; Body Temperature; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Ma | 1967 |
The role of drugs in a malaria program.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui | 1972 |
Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria.
Topics: Adult; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Chloroquine; Deferoxamine; Humans | 1972 |
Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale.
Topics: Africa, Western; Anopheles; Chloroquine; Humans; Malaria; Male; Plasmodium; Quinine; Recurrence; Tim | 1971 |